An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipiodol emulsion containing doxorubicin or doxorubicin loaded into DC Beads in patients with intermediate stage hepatocellular carcinoma (HCC).

Trial Profile

An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipiodol emulsion containing doxorubicin or doxorubicin loaded into DC Beads in patients with intermediate stage hepatocellular carcinoma (HCC).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2013

At a glance

  • Drugs Doxorubicin (Primary) ; Ethiodized oil
  • Indications Liver cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Aug 2013 Planned End Date changed to 23 Jul 2015.
    • 12 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top